KC-2506

Ba/F3-NRAS-G13C-Cell-Line

×
Please enable JavaScript in your browser to complete this form.
43840
Home » 细胞系 » Ba/F3-NRAS-G13C-Cell-Line

Background of Ba/F3-NRAS-G13C-Cell-Line

The N-ras proto-oncogene is a member of the Ras gene family, NRAS protein can bind GDP/GTP and possess intrinsic GTPase activity, NRAS protein participates in RAS-Raf-MEK-ERK pathway, which is responsible for controlling gene transcription activity and cell cycle. Mutations in this gene lead to abnormal persistent activation of downstream genes such as Raf kinases, leading to tumorigenesis. Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.

Specifications

Catalog NumberKC-2506
Cell Line NameBa/F3-NRAS-G13C-Cell-Line
Host Cell LineBa/F3
DescriptionStable Ba/F3 clone expressing exogenous NRAS bearing G13C amino acid mutation
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS
Selection MarkerN/A
MorphologyMostly single, round (some polymorph) cells in suspension
SubcultureSplit saturated culture 1:10 every 3 days; seed out at about 1-3 × 105 cells/mL
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 20 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

Ba/F3 NRAS-G13C cell Line was generated using retrovirus vector expressing human NRAS-G13C sequence.

Characterization

Figure 1: Characterization of NRAS and its mutants overexpressing in Ba/F3 stable clones using PCR sequencing

Figure 1: 1. Harvest and seed the Ba/F3 cells expressing NRAS mutant in 96-well plate (3000 cells/90ul medium). 2. Next day, add 10ul 10X serially diluted compound solution each well and incubate the plates for another 72 hours. 3. Add 100ul Cell Titer-Glo each well, mixed and readout using Envision. 4. Plot the dose-responsive curve and fit the IC50 (the centration of 50% inhibition of DMSO vehicle treated clones) using GraphPad Prism software (Version 5).

Cell Resuscitation

  1. Prewarm culture medium (RPMI1640 + 10% FBS)in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% RPMI-1640 + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage

References

  1. NRAS mutant melanoma: Towards better therapies, Cancer Treatment Reviews, 2021
  2. Targeting mutant NRAS signaling pathways in melanoma. Pharmacological Research. 2016
  3. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
  4. EBioMedicine, 2019
Please enable JavaScript in your browser to complete this form.